Novel bone-targeting agents in prostate cancer.

Area of Science:

• Oncology
• Bone Metastasis Research

Background:

• Prostate cancer (PC) is a leading cause of cancer death in men.
• Bone is the most frequent site for PC metastasis, leading to skeletal-related events (SREs).
• Patients with bone metastases have a median survival of approximately 3 years.

Purpose of the Study:

• To provide an overview of novel bone-targeted therapies for prostate cancer.
• To discuss emerging treatments for PC bone metastases.

Main Methods:

• Review of current literature on bone-targeted agents.
• Analysis of agents in clinical trials for PC bone metastases.

Main Results:

• Several novel bone-targeted agents are available or under evaluation.
• These include bisphosphonates, RANK ligand inhibitors, and others.

Conclusions:

• Emerging bone-targeted therapies offer new treatment avenues for PC.
• These therapies aim to manage SREs and improve survival in metastatic PC.